Treatment of Paget’s Disease with Etidronate Disodium

  • Pierre J. Meunier
  • Alain Ravault


Eighty-eight patients with Paget’s disease were treated with etidronate disodium at an oral dose of 5 mg/kg/d and followed up for an average of 5.2 years. Each course of treatment lasted 6 months and was repeated once or several times. Of the symptomatic patients 75% showed improvement at the end of the follow-up period, whereas 85% of the asymptomatic patients developed no complications that might have been expected if preventive treatment had not been undertaken. Overall, there was clinical deterioration in 28% of the patients during the study. Despite the generally beneficial results, cranial symptoms were not always decreased, and hypoacusis appeared or worsened in some patients. Twenty-three fractures occurred, including eight in pagetic bone, but fracture risk was not increased by etidronate disodium. Extraskeletal side effects were rare. However, there was a delayed exacerbation of bone pain in approximately 12% of patients. This side effect resolved when etidronate disodium was stopped except in one case in which a fracture ensued. Of the patient population 25% were resistant to etidronate disodium; resistance generally appeared between the second and third courses of etidronate disodium treatment. In summary, when etidronate disodium is prescribed over a prolonged period at a dose of 5 mg/kg/d in 6-month courses, the drug improves or stabilizes the condition of three quarters of the patients with Paget’s disease, both clinically and biochemically.


Salmon Calcitonin Human Calcitonin Pagetic Bone Spinal Cord Dysfunction Etidronate Disodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexandre C, Chapuy MC, Bressot C, et al: Traitement de la maladie osseuse de Paget par l’ethanc-1-hydroxy-1, diphosphonate à faible posologic. Nouv Presse Med 1980; 9: 3429–3433.PubMedGoogle Scholar
  2. 2.
    Alexandre C,Chapuy MC, Vignon E, et al: Treatment of Paget’s disease of bone with ethane-1-hydroxy-1, 1-diphosphonate (EHDP) at a low dosage (5 mg/kg/day). Clin Orthop 1983; 174: 193–205.PubMedGoogle Scholar
  3. 3.
    Altman RD, Johnston CC, Khairi MRA, et al: Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone (osteitis deformans). N Engl J Med 1973; 189: 1379–1384.CrossRefGoogle Scholar
  4. 4.
    Canfield RE, Rosner W, Skinner J, et al: Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 1977; 44: 96–106.PubMedCrossRefGoogle Scholar
  5. 5.
    Devries HR, Bijvoet OLM: Results of prolonged therapy with EHDP in Paget’s disease. Neth J Med 1974; 17: 281–298.Google Scholar
  6. 6.
    Finerman GA, Gonick HC, Smith RK, Mayfiel JM: Diphosphonate treatment of Paget’s disease. Clin Orthop 1976; 120: 115–124.PubMedGoogle Scholar
  7. 7.
    Guncaga J, Lauffenburger T, Lentner C, et al: Diphosphonate treatment of Paget’s disease of bone: A correlated metabolic calcium kinetic and morphometric study. Horm Metab Res 1974; 6: 62–69.PubMedCrossRefGoogle Scholar
  8. 8.
    Kantrowitz FG, Byrne MH, Schiller AL, Krane SM: Clinical and biochemical effects of diphosphonates in Paget’s disease of bone, abstracted. Arthritis Rheum 1975; 18: 407.Google Scholar
  9. 9.
    Khairi MRA, Johnston CC, Altman RD, et al: Treatment of Paget’s disease of bone (osteitis deformans): results of a one year study with sodium etidronate. JAMA 1974; 230: 562–267.PubMedCrossRefGoogle Scholar
  10. 10.
    Khairi MRA, Altman RD, De Rosa GP, et al: Sodium etidronate in the treatment of Paget’s disease of bone: A study of long-term results. Ann Intern Med 1977; 87: 656–663.PubMedGoogle Scholar
  11. 11.
    Khairi MRA, Johnston CC: Treatment of Paget’s disease of bone (osteitis deformans) with sodium etidronate. Clin Orthop 977;127:94–105.Google Scholar
  12. 12.
    Rampon S, Bussière JL: Coxopathies pagétiques, In: La Maladie Osseuse de Paget. Premier Colloque de pathologie locomotrice, Montpellier, 1974. Paris, Galliena, 1975 pp 29–34.Google Scholar
  13. 13.
    Renier JC, Bontoux-Carre E, Bontoux L, et al: Le traitement de la maladie de Paget par l’éthane-hydroxy-1, 1-diphosphonate (EHDP). Rev Rhum 1982; 49: 87–92.PubMedGoogle Scholar
  14. 14.
    Ravault A: Maladie osseuse de Paget. Suivi à long terme de 88 patients traites à l’etidron- ate disodique en discontinu à faible dose (5 mg/kg/j). Thesis. Lyon I University, 1986.Google Scholar
  15. 15.
    Siris ES, Canfield RE, Jacobs TP, et al: Clinical and biochemical effects of EHDP in Paget’s disease of bone: Pattern of response to initial treatment and to long-term therapy. Metab Bone Dis 1981; 4–5: 301–308.CrossRefGoogle Scholar
  16. 16.
    Smith R: Paget’s Disease of Bone: Biochemical Disorders of the Skeleton. London, Butterworth Publishers, 1979.Google Scholar
  17. 17.
    Meunier PJ, Saison C, Mathieu L, et al: Skeletal distribution and biochemical parameters of Paget’s disease. Clin Orthop 1987; 217: 37–44.PubMedGoogle Scholar
  18. 18.
    Altman RD: Long-term follow-up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 1985; 79: 583–590.PubMedCrossRefGoogle Scholar
  19. 19.
    Siris ES, Canfield RE, Jacobs TP, Baquiran DC: Long-term therapy of Paget’s disease of bone with EHDP. Arthritis Rheum 1980; 23: 1177–1184.PubMedCrossRefGoogle Scholar
  20. 20.
    Johnston CC, Khairi MRA, Meunier PJ: Use of etidronate (EHDP) in Paget’s disease of bone. Arthritis Rheum 1980; 23: 172–176.CrossRefGoogle Scholar
  21. 21.
    Basle MF, Rebel A, Renier JC, et al: Bone tissue in Paget’s disease treated by ethane-1-hydroxy-1, 1-diphosphonate (EHDP): Structure, ultrastructure and immunocytology. Clin Orthop 1984; 184: 281–288.PubMedGoogle Scholar
  22. 22.
    Charhon S, Chapuy MC, Valentin-Opran A, Meunier PJ: Intravenous etidronate for spinal cord dysfunction due to Paget’s disease. Lancet 1982; 1: 391–392.PubMedCrossRefGoogle Scholar
  23. 23.
    Douglas DL, Duckworth T, Kanis JA, et al: Spinal cord dysfunction in Paget’s disease of bone and its treatment: Has medical treatment a vascular basis? J Bone Joint Surg 1981; 63B: 495–503.Google Scholar
  24. 24.
    Douglas DL, Kanis JA, Duckworth T, et al: Paget’s disease: Improvement of spinal cord dysfunction with diphosphonates and calcitonin. Metab Bone Dis 1981; 3: 327–336.CrossRefGoogle Scholar
  25. 25.
    Nager GT: Paget’s disease of the temporal bone. Ann Otol Rhinol Laryngol 1975;84(suppl 22):l–32.Google Scholar
  26. 26.
    Ibbertson HK, Henley JW, Fraser TR, et al: Paget’s disease of bone-clinical evaluation and treatment with diphosphonate. Aust NZ J Med 1979; 9: 31–35.CrossRefGoogle Scholar
  27. 27.
    Mautalen G, Gonzales D, Blumenfeld E, et al: Spontaneous fractures of uninvolved bones in patients with Paget’s disease during unduly prolonged treatment with disodium etidronate (EHDP). Clin Orthop 1986; 207: 150–155.PubMedGoogle Scholar
  28. 28.
    Altman RD, Collins B: Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 1980; 23: 1121–1127.PubMedCrossRefGoogle Scholar
  29. 29.
    Dickson DD, Camp JD, Ghormley RK: Osteitis deformans: Paget’s disease of the bone. Radiology 1945; 44: 449–455.Google Scholar
  30. 30.
    Nagant, de Deuxchaisnes C, Dufour JP, Devogelaer JP et al: Etidronate and the risk of fractures. Lancet 1985; 1: 610–611.CrossRefGoogle Scholar
  31. 31.
    Traver CA: The association of fractures and Paget’s disease (osteitis deformans). N Y State J Med 1936; 36: 242–246.Google Scholar
  32. 32.
    Bouvet JP: Traitement de la maladie de Paget par la thyrocalcitonine de saumon: Etude coopérative en double insu. Nouv Presse Med 1977; 6: 1447–1450.Google Scholar
  33. 33.
    Burckhardt P, Ducommun J, Hessler C: Treatment of Paget’s disease of bone with human calcitonin, in Mclntyre I (ed): Human Calcitonin and Paget’s Disease Bern, Hans Huber, 1977, pp 155–160.Google Scholar
  34. 34.
    De Rose J, Singer FR, Avramides A, et al: Response of Paget’s disease to porcine and salmon calcitonin. Am J Med 1974; 56: 858–866.CrossRefGoogle Scholar
  35. 35.
    Grunstein HS, Clifton-Bligh P, Posen S: Paget’s disease of bone: Experience with 100 patients treated with salmon calcitonin. Med J Aust 1981; 2: 278–280.PubMedGoogle Scholar
  36. 36.
    Hamilton CR: Effects of synthetic salmon calcitonin in patients with Paget’s disease of bone. Am J Med 1974; 56: 315–322.PubMedCrossRefGoogle Scholar
  37. 37.
    Jaeger P, Bischof F, Delaloye A, Burckhardt P: Le traitement combiné de la maladie de Paget de l’os par la calcitonine et le diphosphonate EHDS, Schweiz Med Wochenschr 1981; 111: 1893–897.PubMedGoogle Scholar
  38. 38.
    Kanis JA, Horn DB, Scott RDM, Strong JA: Treatment of Paget’s disease of bone with synthetic salmon calcitonin. Br Med J 1974; 3: 727–731.PubMedCrossRefGoogle Scholar
  39. 39.
    Kuhlencordt F, Ringe JD, Kruse HP: Behandlung der Ostendystrophia deformans Paget mit Lachs-Calcitonin. Dtsch Med Wochenschr 1981; 106: 1620–1623.PubMedCrossRefGoogle Scholar
  40. 40.
    Lang R, Milkman M, Jensen PS, Vignery AMC: Chronic treatment of Paget’s disease of bone with synthetic human calcitonin. Yale J Biol Med 1981; 54: 355–365.PubMedGoogle Scholar
  41. 41.
    Martin TJ, Jerums G, Melick RA, et al: Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget’s disease of bone. Aust NZ J Med 1977; 7: 36–43.CrossRefGoogle Scholar
  42. 42.
    Nuti R, Vattimo A: Synthetisches human-calcitonin bei Osteodystrophie deformans (Paget) und Osteoporose. Dtsch Med Wochensch 1981; 106: 149–152.CrossRefGoogle Scholar
  43. 43.
    Plehwe WE, Hudson J, Clifton-Bligh P, Posen S: Porcine calcitonin in the treatment of Paget’s disease of bone: Experience with 32 patients. Med J Aust 1977; 1: 577–581.PubMedGoogle Scholar
  44. 44.
    Sturtridge WC, Harrison JE, Wilson DR: Long-term treatment of Paget’s disease of bone with salmon calcitonin. Can Med Assoc J 1977; 117: 1031–1034.PubMedGoogle Scholar
  45. 45.
    Ziegler R, Holz G, Raue F, et al: Therapeutic studies with human calcitonin, in Mclntyre I. (ed): Human Calcitonin and Paget’s Disease. Proceedings of the International Workshop). Bern, Hans Huber, 1977, p. 167.Google Scholar
  46. 46.
    Evans IMA: Human calcitonin in the treatment of Paget’s disease of bone: Long term trials, in Mclntyre I (ed): Human Calcitonin and Paget’s Disease. Bern, Hans Huber, 1977, pp 111–123.Google Scholar
  47. 47.
    Fornasier VL, Stapleton K, Williams CC: Histological changes in Paget’s disease treated with calcitonin. Hum Pathol 1978; 9: 455–461.PubMedCrossRefGoogle Scholar
  48. 48.
    Singer FR, Rude RK, Mius BG: Studies of the treatment and aetiology of Paget’s disease of bone, in Mclntyre I (ed): Human Calcitonin and Paget’s Disease. Bern, Hans Huber, 1977, pp 93–110.Google Scholar
  49. 49.
    Woodhouse NJY, Chalmers AH, Wells IP, et al: Paget’s disease: Radiological changes occurring in untreated patients and those on therapy with salmon calcitonin during two years observation. Br J Radiol 1977; 50: 699–705.PubMedCrossRefGoogle Scholar
  50. 50.
    Fromm G, Schajowicz F, Casco C, et al: The treatment of Paget’s bone disease with sodium etidronate. Am J Med Sci 1979; 277: 29–37.Google Scholar
  51. 51.
    Boyce BF, Fogelman I, Ralston S, et al: Focal osteomalacia due to low-dose diphosphon- ate therapy in Paget’s disease of bone. Lancet 1984; 1: 821–824.PubMedCrossRefGoogle Scholar
  52. 52.
    Evans RA, Dunstan CR, Holls E, Wong SYP: Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget’s disease of bone. Aust NZ J Med 1983; 13: 277–279.CrossRefGoogle Scholar
  53. 53.
    Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP: Roentgenologic evaluation of the action of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) In Paget’s disease of bone, in Mclntyre I. Szelke M (eds): Molecular Endocrinology. Proceedings of Endocrinology 79. Amsterdam, Elsevier North Holland Biomedical Press, 1979, pp 405–433.Google Scholar
  54. 54.
    Alexandre C, Meunier PJ, Edouard C, et al: Effects of ethane-1-hydroxy-1, 1-diphos-phonate (5 mg/day/dose) on quantitative bone histology in Paget’s disease of bone. Metab Bone Dis 1981; 3: 309–316.CrossRefGoogle Scholar
  55. 55.
    Russell RGG, Smith R, Preston C, et al: Diphosphonates in Paget’s disease. Lancet 1974; 1: 894–898.PubMedGoogle Scholar
  56. 56.
    Nagant, de Deuxchaisnes C, Maldague B, Malghem J et al: The action of the main therapeutic regimens on Paget’s disease of bone with a note of the effect of vitamine D deficiency. Arthritis Rheum 1980; 23: 1215–1234.CrossRefGoogle Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • Pierre J. Meunier
  • Alain Ravault

There are no affiliations available

Personalised recommendations